tradmap

HALO Earnings Halozyme Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$1 $1 $3 $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $698M $1B 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$103M $171M $444M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 $0 $2 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $240M $481M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$142M $44M $230M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–60 of 60
Q2 20262026-06-301.902026-08-0610-Q
Q1 20262026-03-311.222026-05-1110-Q
Q4 2025 (derived)2025-12-31-1.132026-02-1710-K
FY 20252025-12-312.562026-02-1710-K
Q3 20252025-09-301.432025-11-0310-Q
Q2 20252025-06-301.332025-08-0510-Q
Q1 20252025-03-310.932025-05-0610-Q
Q4 2024 (derived)2024-12-311.062025-02-1810-K
FY 20242024-12-313.432025-02-1810-K
Q3 20242024-09-301.052024-10-3110-Q
Q2 20242024-06-300.722024-08-0610-Q
Q1 20242024-03-310.602024-05-0710-Q
Q4 2023 (derived)2023-12-310.642024-02-2010-K
FY 20232023-12-312.102024-02-2010-K
Q3 20232023-09-300.612023-11-0610-Q
Q2 20232023-06-300.562023-08-0810-Q
Q1 20232023-03-310.292023-05-0910-Q
Q4 2022 (derived)2022-12-310.412023-02-2110-K
FY 20222022-12-311.442023-02-2110-K
Q3 20222022-09-300.442022-11-0810-Q
Q2 20222022-06-300.162022-08-0910-Q
Q1 20222022-03-310.432022-05-1010-Q
Q4 2021 (derived)2021-12-310.452022-02-2210-K
FY 20212021-12-312.742022-02-2210-K
Q3 20212021-09-301.482021-11-0210-Q
Q2 20212021-06-300.622021-08-0910-Q
Q1 20212021-03-310.192021-05-1010-Q
Q4 20202020-12-310.502021-02-2310-K
FY 20202020-12-310.912021-02-2310-K
Q3 20202020-09-300.252020-11-0210-Q
Q2 20202020-06-300.192020-08-1010-Q
Q1 20202020-03-31-0.042020-05-1110-Q
Q4 20192019-12-31-0.242020-02-2410-K
FY 20192019-12-31-0.502020-02-2410-K
Q3 20192019-09-30-0.17——
Q2 20192019-06-30-0.10——
Q1 20192019-03-310.012019-05-0710-Q
Q4 20182018-12-31-0.012019-02-2110-K
FY 20182018-12-31-0.562019-02-2110-K
Q3 20182018-09-30-0.192018-11-0610-Q
Q2 20182018-06-30-0.16——
Q1 20182018-03-31-0.19——
Q4 20172017-12-31850.002018-02-2010-K
FY 20172017-12-310.452018-02-2010-K
Q3 20172017-09-3020.002017-11-0710-Q
Q2 20172017-06-30-230.00——
Q1 20172017-03-31-260.00——
Q4 20162016-12-310.032017-02-2810-K
FY 20162016-12-31-0.81——
Q3 20162016-09-30-0.23——
Q2 20162016-06-300.022016-08-0910-Q
Q1 20162016-03-31-0.12——
Q4 20152015-12-310.032016-02-2910-K
FY 20152015-12-31-0.25——
Q3 20152015-09-30-0.19——
Q2 20152015-06-300.022015-08-1010-Q
Q1 20152015-03-31-0.12——
Q2 20142014-06-30-0.13——
Q3 20112011-09-300.052011-11-0810-Q
Q2 20112011-06-300.032011-08-0510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.